For research use only. Not for therapeutic Use.
Resolvins are a family of potent lipid mediators derived from both eicosapentaenoic acid (EPA; Item No. <span class=/itemid/>90110</span>) and docosahexaenoic acid (DHA; Item No. <span class=/itemid/>90310</span>). In addition to being anti-inflammatory, resolvins promote the resolution of the inflammatory response back to a non-inflamed state. Resolvin D1 (RvD1) is produced physiologically from the sequential oxygenation of DHA by 15- and 5-lipoxygenase. A 17(R)-epimer (Item No. <span class=/itemid/>13060</span>) of RvD1 can also be generated in aspirin-treated samples. Both RvD1 and its 17(R)-configuration reduce human polymorphonuclear leukocyte (PMNL) transendothelial migration, the earliest event in acute inflammation, with EC<sub>50</sub> values of ~30 nM. RvD1 and its aspirin-triggered form also exhibit a dose-dependent reduction in leukocyte infiltration in a mouse model of peritonitis with a maximal inhibition of ~35% at a 10-100 ng dose. Analytical and biological comparisons of synthetic RvD1 with endogenously derived RvD1 have confirmed its identity as matching the natural product.
| Catalog Number | R030571 |
| CAS Number | 872993-05-0 |
| Synonyms | (4Z,7S,8R,9E,11E,13Z,15E,17S,19Z)-7,8,17-Tihydroxy-4,9,11,13,15,19-docosahexaenoic Acid; |
| Molecular Formula | C22H32O5 |
| Purity | ≥95% |
| Target | Endogenous Metabolite |
| Storage | -80°C |
| InChIKey | OIWTWACQMDFHJG-CCFUIAGSSA-N |
